Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Aug 09, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

Jul 24, 2024

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

Jun 12, 2024

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

Jun 06, 2024

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

May 13, 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

May 13, 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

May 09, 2024

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 08, 2024

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

May 06, 2024

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 28

Investor Tools

Code of Conduct & Business Ethics

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact